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Changes in the response of the RIF-1 tumour to melphalan
in vivo induced by inhibitors of nuclear ADP-ribosyl
transferase
M.R. Horsman, D.M. Brown, D.G. Hirst & J.M. Brown
Division of Radiobiology Research, Department of Radiology, Stanford University, Stanford, CA 94305, USA.
Summary The effect of inhibitors of nuclear ADP-ribosyl transferase (ADPRT) on the cytotoxicity of
melphalan (L-PAM) in the RIF-l tumour in vivo was investigated. A large single dose of nicotinamide
(1000mgkg-') enhanced the tumour cell killing by L-PAM as measured by tumour cell survival. This
enhancement was maximum when nicotinamide was administered within 1 h before injecting the L-PAM.
When given at this time, the nicotinamide had a dose-modifying effect on all L-PAM doses tested, giving rise
to a mean enhancement ratio (ER) of 2.2. Nicotinamide did not appear to inhibit the recovery from L-PAM
induced potentially lethal damage. L-PAM (6mgkg-1) produced a transient drop in mouse body temperature.
This effect was both increased and prolonged by nicotinamide. In addition the inhibitor also delayed the
clearance of L-PAM from the plasma of C3H mice, such that the half-life of the chemotherapeutic agent was
extended from 41 min to 143min. The effect of combining L-PAM with nicotinamide doses below
1000mgkg-' was also investigated. The results showed that as the nicotinamide dose was decreased, the
enhancement of the effects on body temperature, pharmacokinetics and white blood cell counts were reduced.
However, a concomitant loss in the enhancement of tumour cell killing was also observed. Similar results were
obtained using 3-aminobenzamide, a more efficient inhibitor of ADPRT.
A major factor affecting the response of malignant
tumours to various chemotherapeutic agents may
be their ability to repair potentially lethal damage
(PLD). Recovery from PLD has been observed in
tumour cells after drug treatment both in vitro and
in vivo (for review see Bertrand & Deen, 1980). It
remains a possibility that if this repair can be
inhibited a better clinical response following drug
therapy may be achieved.
There is now strong in vitro evidence that the
enzyme, nuclear ADP-ribosyl transferase (ADPRT),
participates in DNA excision repair after exposure
of eukaryotic cells to radiation or alkylating agents,
although the precise molecular involement of the
enzyme is not yet known (for review see Shall,
1982). The activity of this enzyme can be inhibited
by several groups of compounds including thymi-
dine, nicotinamides, benzamides and methylxan-
thines (Preiss et al., 1971; Shall, 1975; Davies et
al., 1978). Combining these inhibitors with DNA
damaging agents has been shown to produce a
significantly greater degree of cell killing than seen
with these agents in the absence of the inhibitor.
This has been reported for the enhancement of
drug-induced damage in vitro (Nduka et al., 1980;
Jacobson et al., 1984) and to a lesser extent in vivo
(Smulson et al., 1977; Sakamoto et al., 1983).
In order to investigate these effects in more
detail, we have studied the effect of two inhibitors
of ADPRT, nicotinamide and 3-aminobenzamide,
on the activity of the bifunctional alkylating agent
melphalan (L-phenylalanine mustard, L-PAM)
against normal and malignant tissues in the mouse.
A preliminary report of this work has been
presented (Brown et al., 1984b).
Materials and methods
Tumour system
The RIF-1 tumour was used in all experiments.
This tumor is a radiation-induced sarcoma which
arose in the inbred female C3H/Km mouse. It is
routinely maintained by passage in vivo and in vitro
according to a published protocol (Twentyman et
al., 1980). Solid tumours were produced in 3-4
month old female C3H/Km mice by inoculating
2 x 105 cells into the gastrocnemius muscle in the
right rear leg. All drug treatments were carried out
when the tumour size was 300-600mg. The
experimental techniques have previously been
described in detail (Horsman et al., 1984).
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Drug treatments
All drug solutions were prepared immediately prior
to injection. Nicotinamide (Sigma Chemical Co., St.
Louis, MO) was dissolved in a sterile saline
solution (0.9% NaCI). 3-aminobenzamide (Sigma)
was prepared by dissolving 100mg in ml absolute
ethanol and diluting in 9ml saline. Subsequent
dilutions were in saline. L-PAM (Burroughs
Wellcome Co., Research Triangle Park, NC) was
prepared by dissolving 10mg in ml 95% ethanol
and 5% HCI. It was further diluted to the required
concentration in a 60% solution of propylene glycol
in saline. Prepared drug concentrations were varied
so that a constant volume (0.01 mlg-1 body weight)
could be injected tor both nicotinamide and L-
PAM. The low solubility of 3-aminobenzamide,
however, necessitated the injection of 0.01 to
0.04mlg-1 body weight depending on the required
final drug concentration. All drugs were injected
i.p.
Tumour studies
Tumour response was assayed by survival of
tumour cells. Survival was determined, as
previously described (Horsman et al., 1984), by
excising tumours at various times, up to and
including 24h, after injecting L-PAM. Three
tumours were combined for each datum point.
They were subsequently minced, enzymatically
disaggregated and single cell suspensions produced.
The enzyme mixture was removed by centrifugation
(1500 r.p.m.; 10min) and the cells resuspended,
counted, serially diluted and plated in Waymouth's
medium+15% foetal calf serum (Gibco, Santa
Clara, CA). The colony-forming ability of these
cells was then determined. Survival was expressed
as surviving fraction g-1 tumour. This is the
product of the plating efficiency and cell yield g-1
of treated tumours relative to that for untreated
tumours.
Normal tissue studies
Previous experiments have shown that the number
of white blood cells (WBC) in the peripheral blood
declines for several days after treatment with
cyclophosphamide (Law et al., 1981) and L-PAM
(Hirst, unpublished) reaching a minimum at 4
days before recovery begins. In our experiments 5Ml
blood samples were taken from the tails of tumour-
bearing mice four days after injecting drugs. The
blood was diluted with 95y1 of 2% glacial acetic
acid to lyze the erythrocytes. The resulting
suspension of leucocytes was counted using a
haemacytometer. Six mice were used for each
treatment group.
Measurement ofplasma L-PAM levels
Plasma L-PAM levels were determined as described
previously (Horsman et al., 1984). Briefly, at
various times after drug injection, mice were bled
by cardiac puncture under diethyl ether anaesthesia
and plasma separated by centrifugation
(3,000r.p.m.; 5min). Drug concentrations were
determined by reverse phase high-performance
liquid chromatography (Waters Associates, Milford,
MA) using the procedure of Furner et al. (1976).
Results were collected on a data module chart
recorder (Waters Associates). Quantitation of drug
concentration was by peak area with reference to
linear calibration curves.
Body temperature measurements
For the RIF-l tumour grown i.m. in the leg of
C3H mice, body temperatures are a good indicator
of tumour temperatures (Horsman et al., 1984).
Drug-induced temperature changes were therefore
determined by measuring mouse body temperatures
at various times after drug injections using a
rectally inserted thermocouple (Bailey Instruments,
Saddle Brooke, NJ).
Results
When tumour-bearing C3H mice were given nico-
tinamide (1000mgkg-1) and L-PAM (6mgkg-1)
in combination, there was an enhancement of cell
killing above that obtained with L-PAM alone
(Figure 1). The effect was maximal when
nicotinamide was given between 1 h before L-PAM
and at the same time as the alkylating agent. This
enhancement was reduced as the time interval
between the drugs increased. Nicotinamide alone
caused a small amount of cell killing. As a
consequence of the results shown in Figure 1, all
further experiments were carried out with the
nicotinamide being administered immediately before
the L-PAM.
The effect of this large single dose of
nicotinamide on the L-PAM dose-response curve,
as measured by tumour cell survival at 24h after
drug treatment, is shown in Figure 2. Increasing
doses of L-PAM caused increasing amounts of cell
kill. Nicotinamide alone had a small effect on the
tumour response. However, when combined with L-
PAM it significantly enhanced the response to the
alkylating agent as demonstrated by a steeper dose
response curve for the two agents combined. The
data shown in Figure 2 suggests that nicotinamide
had a dose-modifying effect for all L-PAM doses,
giving a mean enhancement ratio (ER: calculated as
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Figure 1 The effect of drug timing on tumour cell
survival. Nicotinamide (1000mgkg-') was injected at
various times before or after L-PAM (6mgkg-1) and
survival of RIF-1 tumour cells assayed 24h later: (0)
nicotinamide +L-PAM diluent; (0) nicotinamide +L-
PAM; The shaded area represents L-PAM only.
Means+1 s.e. are shown for 3 to 4 data points.
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Figure 2 The effect of L-PAM +nicotinamide
(1000mgkg-1) in the RIF-1 tumour as measured by
tumour survival at 24h after injection: (0) saline+L-
PAM; (0) nicotinamide +L-PAM. Means+ 1 s.e. are
shown for 4 separate experiments.
that obtained with L-PAM and nicotinamide to
give the same response) of 2.2 (corrected for
nicotinamide toxicity).
Figure 3 shows the effect on survival of varying
the time of removal of tumours from the animals
following an L-PAM injection. When mice were
given saline immediately before a single injection of
L-PAM (6mgkg-1), significant toxicity was seen
even when the tumours were removed within 2h
following the L-PAM dose. The nadir in survival
was reached at 4h and was followed by repair of L-
PAM-induced potentially lethal damage (PLD),
shown by an increasing surviving fraction from 4 to
24h. Nicotinamide alone (1000mgkg -) reduced
survival to - 60% over the 24h period. In
combination with L-PAM, it not only enhanced the
degree of cell killing, but also moved the nadir to
12h. After this time cell survival increased by about
the same amount as seen with L-PAM alone,
although the final survival level was between 11 to
2 decades lower.
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Figure 3 Survival of RIF-1 tumour cells as a function
of time between drug administration and tumour
removal: (A) nicotinamide (1000mgkg-1)+L-PAM
diluent; (0) saline+L-PAM (6mgkg-1); (0)
nicotinamide (1000mgkg-1)+L-PAM (6mgkg-1).
Means+1 s.e. for 4 separate experiments are shown.
Figure 4 shows plasma levels for L-PAM as a
function of time after drug injections. Nicotinamide
(lOOOmgkg-1) given immediately before a dose of
6mgkg-1 L-PAM produced a marked slowing in
the elimination of L-PAM from the blood. The half-250 M.R. HORSMAN et al.
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Figure 4 Plasma levels of L-PAM in tumour-bearing
C3H mice as a function of time after L-PAM
administration: (0) saline+L-PAM (6mgkg-1); (0)
nicotinamide (1000mgkg-')+L-PAM (6mgkg-1).
Each point represents the plasma level from one
mouse, with the results from 3 separate experiments
shown. Lines determined by linear regression analysis
in the regions where exponential decays operated.
life of L-PAM (±1 s.e.), in the region where the
exponential decay operated, was extended from
41min (31-59) to 143min (117-185). Such a change
in L-PAM pharmacokinetics produces a 4-fold
increase in the area under the drug concentration
versus time curve (AUC).
A large single dose of L-PAM (6mgkg-') caused
a drop in rectal temperature of 4°C in C3H mice
(Figure 5). This lower temperature was reached
within 1 h after the injection of L-PAM, but was
followed by recovery such that by 5h the body
temperature had returned to normal. Part of this
effect was a result of the L-PAM diluent, as
previously demonstrated (Horsman et al., 1984).
The injection of nicotinamide alone (1000mgkg-')
produced an effect similar to that seen with L-
PAM. However, when nicotinamide preceded L-
PAM, the fall in body temperature was greater (7-
8°C) and more prolonged: the body temperature
had not returned to normal 8h after giving the
drugs.
In order to test whether an enhancement of L-
PAM tumour cell killing could occur in the absence
of any effect on L-PAM pharmacokinetics or body
temperature, experiments were performed with
reduced nicotinamide doses. As illustrated in
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Figure 5 Mouse body temperature as a function of
time after drug administration: (A) saline+L-PAM
diluent; (El) nicotinamide (1000mgkg-1); (0)
nicotinamide (1000mgkg-1)+L-PAM diluent; (A)
saline+L-PAM (6mgkg-1); (0) nicotinamide
(1000mgkg-1)+L-PAM (6mgkg-1). The shaded area
represents the body temperature of untreated mice.
Means+1 s.e. for 3 to 6 mice are shown.
Figure 6, when the nicotinamide dose injected
immediately before a single dose of L-PAM
(6mgkg-1) was decreased, there was a concomitant
reduction in the fall in mean body temperature
(measured over 6h after drug injection) and the
change in plasma levels of L-PAM (determined 3h
after injection). Below 125mgkg-' nicotinamide
these changes were virtually eliminated. This change
in nicotinamide dose also produced a similar effect
on the L-PAM-induced tumour cell killing, such
that at the doses where no modification of body
temperature or pharmacokinetics were observed, no
significant enhancement of tumour response could
be obtained. The effect of nicotinamide dose on a
normal tissue is shown in Figure 6(d). White blood
cell (WBC) counts were selected because
haemotological effects are the major dose-limiting
problem with alkylating agents. These counts were
determined 4 days after injecting the drugs, when
the WBC nadir is achieved following L-PAM
administration (Hirst, unpublished). Any possible
effect of nicotinamide dose on the subsequent
recovery of WBC counts was not investigated. As
shown in Figure 6(d), the L-PAM-induced
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Figure 6 The effect of different nicotinamide doses on the response to L-PAM (6mgkg-1): (a) Mean mouse
body temperature measured over 6h after drug injection, (b) Plasma L-PAM levels determined at 3h after
drug administration, (c) Tumour survival assayed 24h after L-PAM, (d) WBC counts measured 4 days after
injection ofdrugs. (0) nicotinamide+L-PAM (6mgkg-1). Means+1 s.e. are shown for 3 to 6 data points.
reduction in WBC counts were similarly affected by
changes in nicotinamide dose as reported for the
other endpoints shown in Figure 6.
Since 3-aminobenzamide is a more efficient
inhibitor of ADPRT than nicotinamide (Purnell &
Whish, 1980), we repeated these experiments with
this compound. The results are shown in Figure 7.
Although 3-aminobenzamide was more effective
than nicotinamide on a concentration basis, its
effects on all the end points studied were similar to
those obtained with nicotinamide.
Discussion
The present studies demonstrate that an enhance-
ment of tumour response to the bifunctional
alkylating agent L-PAM can be achieved with
the ADPRT inhibitors nicotinamide and 3-amino-
benzamide. Most of this effect appears to be the
result of an increased plasma half-life of the
chemotherapeutic agent and may not involve any
inhibition of the repair of L-PAM-induced PLD.
Nduka et al. (1980) demonstrated that in L1210
cells the cytotoxicity of methylnitrosourea (MNU)
could be potentiated if these cells were exposed to
non-toxic concentrations of various ADPRT
inhibitors during exposure to the cytotoxic agent
and the subsequent cloning period. Similar results
have been reported for dimethyl sulphate (Durkacz
et al., 1980), streptozotocin (Shall, 1982), methyl
methane sulphonate (Boorstein & Pardee, 1984)
and for recovery from N-methyl-N'-nitro-N-nitro-
soguanidine damage (Jacobson et al., 1984). In
addition, the in vitro cytotoxicity of the bifunctional
alkylating agents nitrogen mustard (Das et al.,252 M.R. HORSMAN et al.
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Figure 7 The effect of different 3-aminobenzamide doses on the response to L-PAM (6mgkg-1): (a) Mean
mouse body temperature measured over 6h after drug injection, (b) Plasma L-PAM levels determined at 3h
after drug administration, (c) Tumour survival assayed 24h after L-PAM, (d) WBC counts measured 4 days
after injection of drugs. (0) 3-aminobenzamide+L-PAM (6mgkg1). Means+ 1 s.e. are shown for 3 to 6
data points.
1982) and L-PAM (Brown et al., 1984b) can be
enhanced by these enzyme inhibitors.
In vivo the results have been far less dramatic.
Smulson et al. (1977) showed that the mean survival
time for L1210 tumour bearing mice could be
increased by treatment with various doses of MNU.
For each MNU dose there was an additional
enhancement of survival time when treatment was
combined with 500mgkg-' nicotinamide.
Sakamoto and colleagues (1983) reported similar
effects for bleomycin and benzamide in Ehrlich
ascites tumour bearing mice. While the effects of
these inhibitors in vitro may be atributed to an
inhibition of PLD repair (Shall, 1982), this may not
be the case in vivo.
A number of studies have clearly shown PLD
repair in vivo following alkylating agent treatment.
This was reported for cyclophosphamide in the
RIF-1 and WHFIB tumours (Law et al., 1981;
Martin et al., 1981), for L-PAM in the KHT, MT,
and RIF-1 tumours (Siemann & Mulcahy, 1982;
Sheldon & Batten, 1982; Horsman et al., 1984), and
for the nitrosoureas CCNU and BCNU in the KHT
sarcoma (Siemann & Mulcahy, 1982). In our studies
we were able to enhance the tumour response to L-
PAM by injecting nicotinamide (lOOOmgkg-1)
immediately before L-PAM (Figure 2). However,
the data of Figure 3 suggest no inhibition of PLD
repair, although an inhibition of L-PAM-induced
PLD repair in vitro has been seen (Brown, D.,
personal communication). The degree of recovery
after alkylating agent damage in vivo is known to
be greater as the nadir of survival goes lower
(Sheldon & Batten, 1982; Horsman et al., 1984).
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Thus, while the similar PLD repair factors, shown
in Figure 3, for L-PAM alone and L-PAM
+nicotinamide do in fact imply some PLD repair
inhibition by nicotinamide, the results are
complicated by at least two factors. First, repair
following L-PAM treatment is complete by 24h
(Horsman et al., 1984). This may not be true for
nicotinamide+L-PAM. Second, the survival nadir
in the combined treatment occurs at 12h after drug
injection, presumably a consequence of the L-PAM
pharmacokinetic changes induced by nicotinamide,
as shown in Figure 4. The continued cell-killing
seen between 6-12h for the combined treatment
may mask any repair occuring during this time
period. In other words, the true survival nadir may
be lower that that actually seen at 12h.
The pharmacokinetic effect of nicotinamide and
3-aminobenzamide may partially be a consequence
of the induced hypothermia shown in Figure 5. The
breakdown of L-PAM in vivo is believed to be
primarily by hydrolysis and alkylation (Evans et al.,
1982). Furthermore, the hydrolysis of L-PAM has
been shown to be temperature sensitive with slower
rates being obtained at lower temperatures, both in
water (Chang et al., 1978) and in plasma (Hinchliffe
et al., 1983). Alternatively, these inhibitors may
actually interfere with these processes or affect some
other metabolic route. Evidence exists showing that
both benzamide and nicotinamide are capable of
changing the levels of various rat liver enzymes
(Blake et al., 1967; Griffin et al., 1984).
Our attempt to show a tumour effect by lowering
the nicotinamide or 3-aminobenzamide doses so
that the pharmacokinetic effect was eliminated
proved generally unsuccessful (Figures 6 and 7). It
is known that the inhibition of repair following
both drug and radiation treatment is dependent
upon the concentration of the inhibitor (Nduka et
al., 1980; Brown et al., 1984a). Decreasing the
inhibitor concentration as shown in Figures 6 and
7, coupled with the metabolism of the inhibitors in
mice, may have reduced the levels to a value too
low to cause an inhibitory effect. By using an
inhibitor with a longer plasma half-life or by
multiple dosing with low levels of nicotinamide or
3-aminobenzamide it may be possible to show PLD
repair inhibition of L-PAM-induced damage, if
indeed it occurs, in the absence of any pharmaco-
kinetic effects.
While much of the enhancement of L-PAM
killing in this tumour model by ADPRT inhibitors
may be explained in the absence of any PLD repair
inhibition, this may not be true for other drugs,
inhibitors or tumour systems. Inhibition of drug-
induced PLD repair has been thought to occur
after treatment with a number of modalities,
including hyperthermia (Braun and Hahn, 1975),
nitroaromatic radiosensitizers (Law et al., 1981;
Martin et al., 1981) and nucleoside analogues (U et
al., 1982; Nakatsugawa et al., 1984). Regardless of
the mechanisms involved, we have found that the
enhancement of drug damage by either ADPRT
inhibitors (Brown et al., 1984b) or nucleoside
analogues (Horsman et al., 1986) can give rise to a
therapeutic gain, albeit at drug doses which are
probably not achievable in humans. Combinations
of anti-tumour drugs and repair inhibitors may
therefore have a clinical role to play. In fact, phase
II trials with the nucleoside analogue Ara-A both as
a radio- and chemosensitizer are currently in
progress in Japan (Nakatsugawa, 1984). However,
the experiments reported in the present study do
suggest that a greater understanding of the
interactions in the in vivo situation are necessary
before such clinical trials are undertaken.
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